Pfizer Says They Saw Durable Responses Seen Against Long Tumors And Brian Metastases Across Multiple Lines Of Therapy In Phase 2 Study Of ALK-Inhibitor Lorlatinib in ALK-Positive and ROS1-Positive Advanced Non-Small Cell Lung Cancer